Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects at least 18 years of age, with a histologically confirmed diagnosis of non-mucinous epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) in first relapse after a first remission of 6 to 18 months duration.~* Subjects must have undergone surgery. Subjects must have received primary chemotherapy, including at least one platinum agent.~* Subject is eligible for retreatment with the same chemotherapy regimen that was used to induce remission (Exception: may reduce the dose of or discontinue taxane if contraindicated due to neurotoxicity.)~* CA125 must have been elevated prior to original chemotherapy.~* CA125 must be elevated at the time of relapse.~* Life expectancy greater than or equal to 6 months, as estimated by the investigator.~* Eastern Cooperative Oncology Group performance status of 0, 1 or 2~* Subjects must consent to use a medically acceptable method of contraception throughout the study period and for 28 days after final MORAb-003 administration, unless surgically sterile.~* Any significant concomitant medical conditions must be well controlled and stable in the opinion of the investigator for at least 30 days prior to Study Day 1.~* Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:~  * Absolute neutrophil count (ANC) ≥ 1.2 x 10e9/L~ * Platelet count ≥ 100 x 10e9/L~ * Hemoglobin ≥ 8 g/dL~* Subject must be willing and able to provide written informed consent. Translations of informed consent information may be provided, subject to the local institutional review board's (IRB's) policy.~Exclusion Criteria:~* Known central nervous system (CNS) tumor involvement.~* Evidence of other active malignancy requiring treatment.~* Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class III or IV, angina not well controlled by medication, or myocardial infarction within 6 months).~* Electrocardiogram (ECG) demonstrating clinically significant arrhythmias (Exception: Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia \[SVT\], are eligible).~* Active serious systemic disease, including active bacterial or fungal infection.~* Active hepatitis or HIV infection.~* Treatment within three months with immunomodulatory therapy (e.g. interferons, immunoglobulin therapy, interleukin 1 receptor antagonist \[IL-1RA\] or systemic corticosteroids). Short term systemic corticosteroids or topical or intra-articular steroids are acceptable, subject to the judgment of the investigator.~* Treatment with a monoclonal antibody therapy AND have evidence of an immune or allergic reaction or documented HAHA.~* Maintenance of first remission by taxane or other chemotherapeutic agent(s).~* Initiation or planned initiation of cancer therapy not given to induce primary remission. Substitutions of agents materially similar to those used in the original regimen are permissible.~* Breast-feeding, pregnant, or likely to become pregnant during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Far Only (Type: EXPERIMENTAL): Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
- Chemo Plus Far (Type: EXPERIMENTAL): Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.

Based on this trial design, predict the completion outcome and termination type (if applicable).